Details for New Drug Application (NDA): 219494
✉ Email this page to a colleague
NDA 219494 describes SPIRONOLACTONE, which is a drug marketed by Amneal, Hetero Labs Ltd Iii, Accord Hlthcare, Actavis Elizabeth, Amneal Pharms, Annora Pharma, Ascot, Aurobindo Pharma, Chartwell Rx, Graviti Pharms, Ivax Pharms, Jubilant Generics, Lederle, Mutual Pharm, Mylan, Oxford Pharms, Pharmobedient, Purepac Pharm, Sun Pharm Industries, Superpharm, Upsher Smith, Vangard, Warner Chilcott, Watson Labs, Zydus Pharms, Parke Davis, and Usl Pharma, and is included in forty-four NDAs. It is available from thirty-eight suppliers. Additional details are available on the SPIRONOLACTONE profile page.
The generic ingredient in SPIRONOLACTONE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
The generic ingredient in SPIRONOLACTONE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
Summary for 219494
| Tradename: | SPIRONOLACTONE |
| Applicant: | Graviti Pharms |
| Ingredient: | spironolactone |
| Patents: | 0 |
Pharmacology for NDA: 219494
| Mechanism of Action | Aldosterone Antagonists |
Medical Subject Heading (MeSH) Categories for 219494
Suppliers and Packaging for NDA: 219494
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SPIRONOLACTONE | spironolactone | TABLET;ORAL | 219494 | ANDA | Rising Pharma Holdings, Inc. | 64980-706 | 64980-706-01 | 100 TABLET in 1 BOTTLE (64980-706-01) |
| SPIRONOLACTONE | spironolactone | TABLET;ORAL | 219494 | ANDA | Rising Pharma Holdings, Inc. | 64980-706 | 64980-706-50 | 500 TABLET in 1 BOTTLE (64980-706-50) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Jan 23, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Jan 23, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Jan 23, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
